NovaBay Pharmaceuticals, Inc. (NBY): Price and Financial Metrics
GET POWR RATINGS... FREE!
NBY Stock Summary
- With a market capitalization of $14,381,876, NovaBay Pharmaceuticals Inc has a greater market value than only 1.58% of US stocks.
- The ratio of debt to operating expenses for NovaBay Pharmaceuticals Inc is higher than it is for about merely 6.24% of US stocks.
- With a year-over-year growth in debt of -72.04%, NovaBay Pharmaceuticals Inc's debt growth rate surpasses only 3.92% of about US stocks.
- Stocks that are quantitatively similar to NBY, based on their financial statements, market capitalization, and price volatility, are MPX, NAII, GNLN, LRN, and HURC.
- Visit NBY's SEC page to see the company's official filings. To visit the company's web site, go to www.novabay.com.
NBY Valuation Summary
- In comparison to the median Healthcare stock, NBY's EV/EBIT ratio is 108.19% lower, now standing at -2.4.
- NBY's EV/EBIT ratio has moved up 12.6 over the prior 169 months.
- NBY's price/sales ratio has moved down 13.3 over the prior 169 months.
Below are key valuation metrics over time for NBY.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| NBY | 2021-08-31 | 3.8 | 2.7 | -3.6 | -2.4 |
| NBY | 2021-08-30 | 3.7 | 2.6 | -3.6 | -2.4 |
| NBY | 2021-08-27 | 3.7 | 2.6 | -3.5 | -2.3 |
| NBY | 2021-08-26 | 3.6 | 2.6 | -3.4 | -2.3 |
| NBY | 2021-08-25 | 3.5 | 2.5 | -3.4 | -2.2 |
| NBY | 2021-08-24 | 3.4 | 2.4 | -3.2 | -2.0 |
NBY Growth Metrics
- The 4 year cash and equivalents growth rate now stands at 299.16%.
- Its year over year cash and equivalents growth rate is now at 84.09%.
- The 3 year net income to common stockholders growth rate now stands at 55.78%.
The table below shows NBY's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-09-30 | 7.668 | -6.319 | -7.42 |
| 2021-06-30 | 7.998 | -6.221 | -8.352 |
| 2021-03-31 | 9.849 | -5.275 | -10.975 |
| 2020-12-31 | 9.934 | -4.721 | -11.039 |
| 2020-09-30 | 9.75 | -4.705 | -12.8 |
| 2020-06-30 | 9.195 | -4.835 | -9.861 |
NBY's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- NBY has a Quality Grade of C, ranking ahead of 44.35% of graded US stocks.
- NBY's asset turnover comes in at 0.533 -- ranking 79th of 680 Pharmaceutical Products stocks.
- AMGN, AMRN, and UTHR are the stocks whose asset turnover ratios are most correlated with NBY.
The table below shows NBY's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.533 | 0.698 | -7.529 |
| 2021-03-31 | 0.660 | 0.610 | -9.044 |
| 2020-12-31 | 0.722 | 0.600 | -7.838 |
| 2020-09-30 | 0.764 | 0.615 | -6.542 |
| 2020-06-30 | 0.757 | 0.607 | -3.607 |
| 2020-03-31 | 0.620 | 0.717 | -1.768 |
NBY Stock Price Chart Interactive Chart >
NBY Price/Volume Stats
| Current price | $0.20 | 52-week high | $0.88 |
| Prev. close | $0.21 | 52-week low | $0.17 |
| Day low | $0.20 | Volume | 833,700 |
| Day high | $0.23 | Avg. volume | 458,407 |
| 50-day MA | $0.26 | Dividend yield | N/A |
| 200-day MA | $0.42 | Market Cap | 10.47M |
NovaBay Pharmaceuticals, Inc. (NBY) Company Bio
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes non-antibiotic anti-infective products for the eye care market in the United States. The company was founded in 2000 and is based in Emeryville, California.
Latest NBY News From Around the Web
Below are the latest news stories about NovaBay Pharmaceuticals Inc that investors may wish to consider to help them evaluate NBY as an investment opportunity.
NovaBay Pharmaceuticals Engages Leading Chinese Marketing Firm to Drive Consumer Sales of DERMAdoctor Skincare Products in ChinaEMERYVILLE, Calif., February 23, 2022--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces the engagement of one of China’s leading marketing firms for omnichannel integrated marketing and branding services of DERMAdoctor skincare products in China. NovaBay’s new marketing partner will also manage DERMAdoctor’s online flagship store on Tmall.com, the leading business-to-cons |
NovaBay Pharmaceuticals Announces Changes to Its Board of DirectorsEMERYVILLE, Calif., January 28, 2022--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focused on developing and commercializing high-quality, scientifically formulated products for the eyecare and skincare markets, announces the appointments of Audrey Kunin, M.D. and Julie Garlikov to the NovaBay Board of Directors. Dr. Kunin is a recognized leader in the skincare product industry and has served as NovaBay’s Chief Product Officer since its acquisition in November 20 |
NovaBay Pharmaceuticals to Donate 2.5 Million KN95 MasksEMERYVILLE, Calif., January 20, 2022--NovaBay Pharmaceuticals donates 2.5 million KN95 protective masks. |
NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of StockholdersEMERYVILLE, Calif., January 20, 2022--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company"), a pharmaceutical company focused on developing and commercializing high-quality, scientifically formulated products for the eyecare and skincare markets, announces that its Special Meeting of Stockholders held on December 17, 2021, as adjourned to and reconvened on January 14, 2022, has been further adjourned until January 31, 2022 at 11:00 a.m. Pacific time in order to provide |
NovaBay Pharmaceuticals Expands Its Eyecare Product Portfolio With the Launch of Lubricating Eye Drops for the Immediate Relief of Dry Eye SymptomsEMERYVILLE, Calif., January 10, 2022--NovaBay Pharmaceuticals launches Avenova Lubricating Eye Drops for the immediate relief of dry eye symptoms. |
NBY Price Returns
| 1-mo | -23.05% |
| 3-mo | -30.99% |
| 6-mo | -57.08% |
| 1-year | -70.77% |
| 3-year | -30.41% |
| 5-year | -92.45% |
| YTD | -46.89% |
| 2021 | -45.97% |
| 2020 | 8.91% |
| 2019 | -16.88% |
| 2018 | -80.00% |
| 2017 | 16.67% |
Continue Researching NBY
Want to see what other sources are saying about NovaBay Pharmaceuticals Inc's financials and stock price? Try the links below:NovaBay Pharmaceuticals Inc (NBY) Stock Price | Nasdaq
NovaBay Pharmaceuticals Inc (NBY) Stock Quote, History and News - Yahoo Finance
NovaBay Pharmaceuticals Inc (NBY) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...